BioSpace News Archive

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of clinical data from Neurona’s ongoing Phase I/II clinical trial of NRTX-1001 in people with mesial temporal lobe epilepsy (MTLE) as well as supporting preclinical and manufacturing data at the annual meeting of the American Epilepsy Society.

China Pharma Holdings, Inc. today announced the Acquisition of Dry Eye Disease Therapeutic Device Project.

Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective study of patients who have received Wharton’s Jelly applications to the SI Joint.

Trialjectory announced it is currently working with more than 50 pharmaceutical companies, emerging biotechs and Contract Research Organizations to develop and execute clinical trials that focus more on patients’ unique medical and personal needs – an increase of 800 percent since the beginning of 2020.

Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at the 22nd Annual Society of Urologic Oncology Meeting demonstrating that Blue Light Cystoscopy decreases the risk and prolongs time to recurrence based on Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with Cysview® Registry database.

The first Integrated Bladder Cancer Center in Hainan Province was inaugurated in Hainan General Hospital at the Hainan Provincial Urology Annual Meeting.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IDEAYA’s development program investigating darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor, for the treatment of adult patients with metastatic uveal melanoma.

TFF Pharmaceuticals, Inc. announced that Glenn Mattes will step down as Chief Executive Officer and Member of the Board of Directors.

Arch Therapeutics, Inc. today announced that the Centers for Medicare and Medicaid Services (“CMS”) has made a preliminary recommendation to establish a dedicated Healthcare Common Procedure Coding System (“HCPCS”) Level II billing code specific to AC5 ® Advanced Wound System (“AC5”).

Protalix BioTherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease.